Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 May 18;257:115503. doi: 10.1016/j.ejmech.2023.115503

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 Elsevier Masson SAS. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 6 — Selected bioactive natural products in COVID-19 therapy and clinical candidate cepharanthine. (a) Chemical structures of selected SARS-CoV-2 inhibitors (Ursodeoxycholic acid, initial study from UK; Gallinamide A, initial study from Australia; Plitidepsin, initial study from USA; Bafilomycin B₂ and Cepharanthine, initial studies from China) for COVID-19 treatment. (b) Important milestones in progress cepharanthine inhibition of SARS-CoV-2. This timeline shows the speed with which drugs can be developed with collaboration.